Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	373.55	370.27	236.12	341.58	64.25	63.02
Trading Asset Securities	149.77	144.72	157.16	236.56	14.4	14.4
Cash & Short-Term Investments	523.32	515	393.28	578.14	78.65	77.42
Cash Growth	33.06%	30.95%	-31.97%	635.07%	1.59%	25.24%
Accounts Receivable	269.03	296.53	265	245.28	192.91	220.59
Other Receivables	5.04	3.69	3.99	4.17	3.98	3.43
Receivables	274.07	300.22	268.98	249.45	196.89	224.02
Inventory	116.62	115.55	107.37	104.65	110.01	78.34
Other Current Assets	28.02	21.27	17.23	25.06	28.21	29.01
Total Current Assets	942.03	952.04	786.86	957.29	413.77	408.79
Property, Plant & Equipment	252.95	246.55	231.12	240	241.77	224.15
Long-Term Investments	0.37	0.37	0.37	0.35	0.42	0.85
Goodwill	100.55	100.55	100.55	100.55	100.55	100.55
Other Intangible Assets	129.35	133.37	148.04	42.08	47.45	52.26
Long-Term Deferred Tax Assets	4.68	4.64	3.05	1.8	1.74	1.83
Long-Term Deferred Charges	8.65	8.7	10.68	16.83	18.28	19.76
Other Long-Term Assets	57.68	58.3	56.81	47.18	45.11	40.68
Total Assets	1,496	1,505	1,337	1,406	869.09	848.86
Accounts Payable	47.77	49.49	30.94	36.88	33.64	45.95
Accrued Expenses	32.47	132.83	141.69	141.02	128.52	147.3
Current Portion of Long-Term Debt	11.37	10.09	-	-	-	-
Current Portion of Leases	-	1.27	0.88	-	-	-
Current Income Taxes Payable	10.77	6.52	10.21	11.23	8.19	12.69
Current Unearned Revenue	27.33	24.61	14.01	28.15	16.15	13.89
Other Current Liabilities	82.82	13.6	12.04	10.31	12.73	14.35
Total Current Liabilities	212.53	238.42	209.77	227.58	199.22	234.18
Long-Term Debt	185	185	-	-	-	-
Long-Term Leases	1.38	1.52	0.46	-	-	-
Long-Term Unearned Revenue	9.38	9.96	11.92	14.05	15.88	18.06
Long-Term Deferred Tax Liabilities	11.48	11.96	12.17	11.45	11.74	10.1
Total Liabilities	419.77	446.86	234.31	253.08	226.84	262.34
Common Stock	102.89	102.89	70.14	70.14	52.6	52.6
Additional Paid-In Capital	641.24	638.71	671.51	664.63	239.22	239.22
Retained Earnings	391.55	375.25	392.32	418.23	350.43	294.7
Treasury Stock	-59.18	-59.18	-30.78	-	-	-
Total Common Equity	1,077	1,058	1,103	1,153	642.25	586.52
Shareholders' Equity	1,077	1,058	1,103	1,153	642.25	586.52
Total Liabilities & Equity	1,496	1,505	1,337	1,406	869.09	848.86
Total Debt	197.75	197.88	1.34	-	-	-
Net Cash (Debt)	325.57	317.12	391.94	578.14	78.65	77.42
Net Cash Growth	-16.93%	-19.09%	-32.21%	635.07%	1.59%	49.41%
Net Cash Per Share	3.24	3.14	3.81	6.85	1.01	1.06
Filing Date Shares Outstanding	99.73	101.08	100.99	103.8	77.85	77.85
Total Common Shares Outstanding	99.73	99.73	102.76	103.8	77.85	77.85
Working Capital	729.49	713.62	577.09	729.7	214.55	174.61
Book Value Per Share	10.79	10.61	10.74	11.11	8.25	7.53
Tangible Book Value	846.6	823.74	854.59	1,010	494.25	433.71
Tangible Book Value Per Share	8.49	8.26	8.32	9.73	6.35	5.57
Buildings	-	289.03	287.63	275.1	274.06	239.09
Machinery	-	301.77	302.77	271.99	263.51	237.07
Construction In Progress	-	40.37	8.82	35.68	23.84	46.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.